Year: 2026
Type: review
Abstract: Cancer immunotherapy has demonstrated remarkable efficacy across multiple tumor types. Despite their significant clinical benefits, most patients with solid tumors remain refractory to immunotherapy, and initial responders frequently develop acquired resistance. Tumor plasticity is a key driver of resistance to cancer immunotherapy. In this review, we discuss how epigenetic and metabolic plasticity of tumor contributes to immunotherapy resistance and highlight emerging strategies targeting these programs to overcome resistance and improve clinical outcomes.
Source: Frontiers in Immunology
Authors: Jee-Eun Choi, Inwha Baek
Institutions: Queen Mary Hospital, University of Hong Kong, Kyung Hee University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7220367516